Interleukin-12 subunit beta (IL-12 p40) (IL-12B)

The Interleukin-12 subunit beta, commonly known as the p40 subunit, is a critical cytokine component that dimerizes with either the p35 subunit to form Interleukin-12 (IL-12) or the p19 subunit to form Interleukin-23 (IL-23) (UniProt: P29460). IL-12 is essential for the differentiation of naive T cells into Th1 cells, which produce interferon-gamma, while IL-23 is vital for the maintenance and expansion of Th17 cells (PubMed: 15661901). Both pathways play central roles in the adaptive immune response and the pathogenesis of various chronic inflammatory and autoimmune disorders (NCBI Gene: 3593). Overexpression or dysregulation of these cytokines is strongly linked to conditions such as psoriasis, Crohn's disease, and ulcerative colitis (StatPearls: NBK537220). Therapeutically, the p40 subunit is a major target for monoclonal antibodies like ustekinumab (DrugBank: DB05609). By binding specifically to the shared p40 protein, these drugs effectively neutralize the bioactivity of both IL-12 and IL-23, reducing the downstream production of pro-inflammatory cytokines (PubMed: 18039401). This dual inhibition has proven highly effective in managing moderate-to-severe autoimmune diseases where both Th1 and Th17 pathways are implicated. However, because these cytokines are involved in host defense, targeting p40 can increase the risk of serious infections and requires careful patient monitoring (FDA: Stelara Label).

Other names

Interleukin-12 subunit p40IL-12BNatural killer cell stimulatory factor 2Cytotoxic lymphocyte maturation factor 2CLMF p40NKSF2

Monoclonal antibodies bind to the p40 subunit of IL-12 and IL-23, preventing their interaction with the IL-12Rβ1 receptor protein on the surface of immune cells, thereby inhibiting Th1 and Th17 mediated inflammatory pathways (DrugBank: DB05609).